# Sheng Han

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sheng-han/

## Facts

| Field | Value |
| --- | --- |
| Citations | 573 |
| Field | Health Systems, Economic Evaluations, Quality of Life |
| h-index | 15 |
| i10-index | 20 |
| Last Known Institution | Peking University |
| OpenAlex ID | https://openalex.org/A5101723313 |
| ORCID iD | 0000-0001-5975-3574 |
| Works | 79 |

## Researcher papers

- [The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China](https://scholariq.org/papers/the-impacts-of-government-reimbursement-negotiation-on-targeted-anticancer/)
- [Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry](https://scholariq.org/papers/management-and-1-year-outcomes-of-patients-with-newly-diagnosed-atrial/)
- [Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China](https://scholariq.org/papers/prices-and-clinical-benefit-of-national-price-negotiated-anticancer-medicines-in/)
- [Effectiveness of hierarchical medical system policy: an interrupted time series analysis of a pilot scheme in China](https://scholariq.org/papers/effectiveness-of-hierarchical-medical-system-policy-an-interrupted-time-series/)
- [Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia](https://scholariq.org/papers/reduced-medical-costs-and-hospital-days-when-using-oral-arsenic-plus-atra-as-the/)
- [Impact of house price growth on mental health: Evidence from China](https://scholariq.org/papers/impact-of-house-price-growth-on-mental-health-evidence-from-china/)
- [Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry](https://scholariq.org/papers/risk-profiles-and-one-year-outcomes-of-patients-with-newly-diagnosed-atrial/)
- [Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China](https://scholariq.org/papers/cost-effectiveness-of-alectinib-for-patients-with-untreated-alk-positive-non/)
- [Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China](https://scholariq.org/papers/can-locally-developed-me-too-drugs-aid-price-negotiation-an-example-of-cancer/)
- [Clinical and economic analysis of Gastrodin injection for dizziness or vertigo: a retrospective cohort study based on electronic health records in China](https://scholariq.org/papers/clinical-and-economic-analysis-of-gastrodin-injection-for-dizziness-or-vertigo-a/)
- [Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study](https://scholariq.org/papers/hospital-healthcare-resource-utilization-and-associated-hospital-costs-of/)

## Researcher topics

- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Pharmaceutical Economics and Policy](https://scholariq.org/topics/pharmaceutical-economics-and-policy/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Researcher university

- [Peking University](https://scholariq.org/institutions/peking-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.